Sitemap

Pages

• 90 years of HA
• About us
  • Company & Values
    • History
    • Latest Investments
    • Production department
  • Compliance
  • CSR Commitments
  • Executive leadership
• Biopolymers portfolio
• Career
  • Nos Métiers
  • Prepare your Interview
• Contact
• Cookies Policy
• Excellence in Quality
• Home
• Industrial Platform
• Innovation & R&D
  • Start-up funding
• Innovation and R&D Support
• International Presence
• Legal Notice & GTC
• Our R&D Laboratories & Facilities
  • Biotech Laboratory
  • Chemistry Laboratory
• Premium Services
• Privacy Policy
• Regulatory Support
• Services
  • Academic Partnership & Patents
  • Functionalized Biopolymers Services
• Sitemap
• Terms & Conditions of Sale

Posts by category

• Category: Non classé

Blog

• Dry Eye Disease (DED): HA at the Heart of Therapeutic Solutions
• Understanding the Role of Salmon Origin in Polynucleotide Quality
• Microneedles: A promising technology for the future of medicine
• Sterile Hyaluronic Acid: Powering HA-based Next Generation of Medical Innovation
• HTL Biotechnology’s Premium Services : A Trusted Partner in Innovation
• ISO 13485 certification renewal: Strengthening the Foundations of Quality Excellence
• The Evolving Role of Hyaluronic Acid in Osteoarthritis and Rheumatology
• Excellence in Quality: The Foundation of HTL Biotechnology’s Pharma-Grade Biopolymers
• Industrial Performance and Corporate Social Responsibility: Interview with Christophe Coyard
• Transforming Vision: Hyaluronic Acid in Ophthalmology
• The Future of Hyaluronic Acid: A Smart Biomaterial for the Next Generation of Medicine
• The HTL Edge: Insights from Experts
• Polynucleotides: A Breakthrough in Regenerative Medicine
• Decoding Hyaluronic Acid: Its Biological Function and Uses
• HTL Biotechnology: A path toward Innovation and Global Leadership

News

• EcoVadis Platinum Level Achieved in 2026
• HTL Biotechnology at PCHi 2026 in Hangzhou
• Lunar New Year 2026: Entering the Year of the Fire Horse
• HTL Biotechnology at IMCAS 2026: advancing the future of regenerative medicine
• HTL Biotechnology joins the Choiseul Conquérants 2025 ranking
• HTL Inside Webinar: a success that boosts our visibility in Asia
• HTL Biotechnology rallies for Pink October 2025
• HTL Biotechnology wins the Responsible Care 2025 Award
• Looking Back at Our Presence at ESCRS 2025
• 2024 CSR Report is now available!
• Strong Presence at ISHAS Congress 2025 in the USA
• HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
• HTL Biotechnology supports National Biomedicines manufacturing Day
• François Fournier Featured in Korean Press
• HTL Biotechnology at AMWC Monaco 2025
• HTL Biotechnology at CIBE China
• The HTL Edge: Insights from Experts
• Our participation at PCHI in China
• HTL Biotechnology at IMCAS 2025
• Certification ISO 13485
• Release of our first CSR Report!
• Happy New Year 2025
• Discover our new webpage dedicated to 90 years of HA and download our White Paper!
• HTL Biotechnology at CPHI Milano
• 1st symposium for HTL Biotechnology at MAIS congress
• HTL Biotechnology will launch its White Paper at CPHI Milan!
• New Certification for HTL Biotechnology
• HTL Biotechnology Secures Medical Device Registration in China
• HTL Biotechnology at CPHI China 2024
• Discover our Quality Policy
• National Bioproduction and Biomedicine Day (TVR report)
• New Ecovadis Gold label 2024
• BIOPHTA 6.5 million Euros Seed Funding
• Acquisition of the Modern Meadow’s human recombinant collagen platform for beauty and biomedical applications
• HTL Biotechnology at In-cosmetics Global Congress in Paris
• France BioLead Membership
• Attending AMWC in Monaco
• HTL Biotechnology at PCHI
• Podcast : Discussion with François Fournier
• Our booth at China International Beauty Expo
• HTL Biotechnology spotlight at Dubai Derma
• 90 years of Hyaluronic Acid with HTL Biotechnology
• Happy Lunar New Year 2024 !
• HTL Biotechnology at IMCAS world congress 2024
• HTL Biotechnology will be at IMCAS 2024 !
• Happy New Year from the HTL Biotechnology team !
• HTL at CPHI 2023 Barcelona
• Our new CSR strategy
• HTL at CPHI Japan 2023
• SFB & TERMIS Americas
• HTL team in Korea and China
• HTL participation at IMCAS
• François Fournier as new CEO
• GelMEDIX investment
• Montagu as new investor
• HTL launches a new bioproduction unit HTL4
• BMG Pharma and HTL sign a development agreement
• Eirion Therapeutics Announces Strategic Agreement
• Terasaki Institute Memorandum of Uderstanding
• HTL Biotechnology & Echelon Biosciences strategic partnership

Products

• Recombinant Human Collagen III
• Hyaluronic Acid (Sodium Hyaluronate)
• Polynucleotides (PDRN - PN)
• Sodium DNA
• Heparosan
• Oligo HA

News types

• Articles
• Press releases

Product categories

• Innovation Portfolio
• Product Portfolio